Sutro Biopharma, Inc. (STRO)
15.80
+0.88
(+5.90%)
USD |
NASDAQ |
Jan 21, 16:00
16.49
+0.69
(+4.37%)
Pre-Market: 08:36
Sutro Biopharma Cash from Investing (Quarterly): 39.99M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| GT Biopharma, Inc. | 0.00 |
| Daré Bioscience, Inc. | -0.1747M |
| Syndax Pharmaceuticals, Inc. | 72.43M |
| Crinetics Pharmaceuticals, Inc. | 164.81M |
| NovaBay Pharmaceuticals, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -38.19M |
| Cash from Financing (Quarterly) | 0.102M |
| Free Cash Flow | -225.11M |
| Free Cash Flow Per Share (Quarterly) | -4.529 |
| Free Cash Flow to Equity (Quarterly) | -46.30M |
| Free Cash Flow to Firm (Quarterly) | -28.77M |
| Free Cash Flow Yield | -52.62% |